The COVID-19 pandemic continues to evolve and have a significant impact on communities throughout the world. We are committed to doing our part to protect patients and communities while continuing to progress our clinical programs. We are closely monitoring developments and guidance from government and health authorities and support the public health strategies being implemented to slow the spread of the disease. We will provide updates as needed as the situation evolves.

Clinical Trials

We are continuing to work proactively with our CRO partners to enable studies to continue with as little interruption as possible and mitigate the potential impact of COVID-19 on our progress.

Business Outlook

We are committed to continuing the growth of our business operations to serve the needs of our patients and advance our mission to develop disruptive treatments for substance use disorders. Given the ongoing uncertainty surrounding the pandemic, we do not know how COVID-19 could impact our business operations going forward. We continue to monitor the situation closely and are working diligently with our research partners and stakeholders to continue our research efforts. We intend to provide updates on our business operations and financial situation quarterly.

Safe Harbor

This business update includes forward-looking statements based on our current expectations and beliefs that are subject to risks and uncertainties. Our actual results may differ materially. Please consult the risk factors section of our SEC filings.